top of page
csm_library_d5279cad79.jpg

Publications

  1. Goldberg Z, Vogt Sionov R, Berger M, Zwang Y, Perets R, Van Etten RA, Oren M, Taya Y, Haupt Y. Tyrosine phosphorylation of Mdm2 by c-Abl: implications for p53 regulation, EMBO J. 2002 Jul 15;21(14):3715-27.

  2. Laury AR, Hornick JL, Perets R, Krane JF, Corson J, Drapkin R, Hirsch MS. PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma. Am J Surg Pathol. 2010 May; 34(5):627-35.

  3. Laury AR, Perets R, Piao H, Krane JF, Barletta JA, French C, Chirieac LR, Lis R, Loda MF, Hornick JL, Drapkin R, Hirsch MS A comprehensive analysis of PAX8 expression in human epithelial tumors.  Am J Surg Pathol. 2011 Jun;35(6):816-26.

  4. Perets R, Kaplan T, Stein I, Hidas G, Tayeb S, Avraham E, Ben-Neriah Y, Simon I, Pikarsky E. Genome-wide analysis of androgen receptor targets reveals COUP-TF1 as a novel player in human prostate cancer. PLoS One 2012, 7, e46467.

  5. Perets R, Wyant GA, Muto KW, Bijron JG, Poole BB, Chin KT, Chen JH, Ohman AW, Stepule CD, Kwak S, Karst AM, Hirsch MS, Setlur SR, Crum CP, Dinulescu DM, Drapkin R. Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca/Tp53/Pten models.  Cancer Cell, 2013, Dec 9th,24(6):751-65

  6. Perets R, Drapkin R, It’s totally tubular… Riding the new wave of ovarian cancer research. Cancer Research, 2016, Cancer Research, 2016, Jan 1st, 76(1), 10-7. 

  7. Sarkar S, Bristow CA, Dey P, Rai K, Perets R, Ramirez-Cardenas A, Malasi S, Huang-Hobbs E, Haemmerle M, Wu SY, McGuire M, Protopopov A, Jiang S, Liu JF, Hirsch MS, Chang Q, Lazar AJ, Sood AK, Drapkin R, DePinho R, Draetta G, Chin L. PRKCI promotes immune suppression in ovarian cancer, Genes & Development, 2017, Jun 1;31(11):1109-1121

  8. Perets R, Greenberg O, Shentzer T, Semenisty V, Epelbaum R, Bick T, Sarji S, Ben-Izhak O, Sabo E, Hershkovitz D, Mutant KRAS ctDNA is an accurate tool for pancreatic cancer monitoring, The oncologist, 2018 May;23(5):566-572

  9. Ghannam-Shahbari D, Jacob E, Kakun RR, Wasserman T, Korsensky L, Sternfeld O, Kagan J, Bublik DR, Aviel-Ronen S, Levanon K, Sabo E, Larisch S, Oren M, Hershkovitz D, Perets R, PAX8 activates a p53-p21-dependent pro-proliferative effect in high grade serous ovarian carcinoma, Oncogene. 2018 Apr;37(17):2213-2224.

  10. Maurice-Dror C, Perets R, Bar-Sela G, Glucocorticoids as an adjunct to oncologic treatment in solid malignancies – Not an innocent bystander, Critical reviews in hematology/oncology, 2018, Jun;126:37-44.

  11. Geva R, Lopez J, Danson S, Joensuu H, Peer A, Harris SJ, Souza F, Pereira KMC, Perets R, Radium-223 in combination with paclitaxel in cancer patients with bone metastases: safety results from an open-label, multicenter phase Ib study, European Journal of Nuclear Medicine and Molecular Imaging. 2018 Dec 13, May;46(5):1092-1101.

  12. Chung HC, Ros W, Delord JP, Perets R, Italiano A, Shapira-Frommer R, Manzuk L, Piha-Paul SA, Xu L, Zeigenfuss S, Pruitt SK, Leary A. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: Results from the phase II KEYNOTE-158 study. Journal of Clinical Oncology. 2019, Jun 10;37(17):1470-1478.

  13. Eckert MA, Coscia F, Chryplewicz A, Chang JW, Hernandez KM, Pan S, Tienda SM, Nahotko DA, Li G, Blaženović I, Lastra RR, Curtis M, Yamada SD, Perets R, McGregor SM, Andrade J, Fiehn O, Moellering RE, Mann M, Lengyel E, Proteomics reveals NNMT as a master metabolic regulator of cancer associated fibroblasts. Nature, 2019, May;569(7758):723-728.

  14. Gabizon AA, Tahover E, Golan T, Geva R, Perets R, Amitay Y, Shmeeda H, Ohana P, Pharmacokinetics of mitomycin-c lipidic prodrug entrapped in liposomes and clinical correlations in metastatic colorectal cancer patients. Investigational New Drugs, 2020, Oct;38(5):1411-1420.

  15. Maniati E, Berlato C, Gopinathan G, Heath O, Kotantaki P, Lakhani A, McDermott J, Pegrum C, Delaine-Smith RM, Pearch OMT, Hirani P, Joy JD, Szabova L, Perets R, Sansom OJ, Drapkin R, Bailey P, Balkwill FR,Mouse ovarian cancer models recapitulate the human tumor microenvironment and patient response to treatment. Cell Reports, 2020, January, 30 (2), 525-540.e7

  16. Taha T, Reiss A, Amit A, Perets R, Checkpoint inhibitors in gynecological malignancies: are we there yet? BioDrugs, 2020 Dec; 34 (6):749-762.

  17. Perets R, Bar J,  Rasco DW,  Ahn M-J, Yoh K , Kim D-W, Nagrial A, Satouchi M ,Lee DH, Spigel DR, Kotasek D, Gutierrez M, Niu J, Siddiqi S, Li X, Cyrus J, Chackerian A, Chain A, Altura RA, Cho BC.Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small cell lung cancer. Annals of Oncology, 2021, In press

  18. Moskovich D, Alfandari A, Finkelshtein Y, Weisz A, Katzav A, Kidron D, Edelstein E, Veroslavski D, Perets R, Arbib N, Kadan Y, Fishman A, Lerer B, Ellis M, Ashur-Fabian O, DIO3, the thyroid hormone inactivating enzyme, promotes tumorigenensis and metabolic reprogramming in high grade serous ovarian cancer. Cancer Letters 2021 Mar 31;501:224-233.

  19. Fares B, Berger L, Bangiev E, Kakun RR, Ghannam-Shahbari D, Tabach Y, Zohar Y, Gottlieb E, Perets R. PAX8 plays an essential anti apoptotic role in uterine serous papillary cancer, Oncogene, 2021, July 9th, v. 40 pp. 5275-5285

  20. Falchook GS, Peeters M, Rottey S, Dirix LY, Obermannova R, Cohen JE, Perets R, Shapira-Frommer R, Bauer TM, Wang JS, Carvajal RD, Sabari J, Chapman S, Zhang W, Calderon B, Peterson DA, A Phase 1a/1b Trial of CSF-1R Inhibitor LY3022855 in Combination with Durvalumab or Tremelimumab in Patients with Advanced Solid Tumors, Investigational New Drugs, 2021, 2021 Oct;39(5):1284-1297

  21. Cho BC, Yoh K, Perets R, Nagrial A, Spigel DR, Gutierrez M, Kim DW, Kotasek D, Rasco D, Niu J, Satouchi M, Ahn MJ, Lee DH, Maurice-Dror C, Siddiqi S, Ren Y, Altura RA, Bar J, Anti–cytotoxic T-lymphocyte–associated antigen-4 monoclonal antibody quavonlimab in combination with pembrolizumab: safety and efficacy from a phase I study in previously treated extensive-stage small cell lung cancer, Lung Cancer, 2021, Sep;159:162-170

  22. Saleh A and Perets R, Mutated p53 in HGSC – From a common mutation to a target for therapy, Cancers, 2021, 13 (14), 3465

  23. Siu LL, Wang D, Hilton J, Geva R, Rasco D, Perets R, Abraham AK, Wilson DC, Markensohn JF, Lunceford J, Suttner L, Siddiqi S, Altura RA, Maurice-Dror C. First-in-Class Anti-immunoglobulin-like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors, Clinical Cancer Research, 2022, Jan, 1;28(1):57-70

  24. Kakun RR, Melamed Z, Perets R, PAX8 in the junction between development and cancer, International Journal of Molecular Sciences, 2022, in press.

bottom of page